Liver diseases are one of the global health care problems with enormous social, economic and clinical consequences
accounting for death. Liver disease constitutes about 10% of all diseases. According to WHO liver disease was the 10th leading
cause of death. Liver disease accounts for approximately 2 million deaths per year worldwide in which 1 million due to
complications of cirrhosis and 1 million due to viral hepatitis and hepatocellular carcinoma. Cirrhosis is likely to be
underestimated as almost 3/4th of patients remain asymptomatic until their liver is irreversibly damaged. Many of the drug
related problems were also raised during the treatment of various liver disorders. To enlist drugs used in the treatment to
categorize the details of the drug for better rational drug use to improve patient quality of life. To reduce the risk of disease and
evaluate the utilization and effectiveness of hepatoprotective agents along with the utilization of antimicrobials. To assess the
severity of disease by using MELD score in hospitalized patient. A prospective observational study was conducted in general
medicine department in tertiary care hospital for a period of 6 months, patients with or without co-morbidities was included in
the study. In a total of 150 patients, DCLD is the most common liver disorder seen in these patients. Most of the liver disorders
are seen in between age groups 30-50 years. In this study ascites is the most seen complication next to encephalopathy and
portal hypertension. The severity of the disease was accessed by using MELD score. The study emphasizes the need to improve
awareness of the patients on liver disease to promote early diagnosis, and reduce the mortality of the hospitalized patients.
There is a considerable scope to improve prescribing patterns in various liver disorders by reducing drug use and lowering drug
doses to decrease the risk of hepatotoxicity and antibiotic resistance. As a result, clinical pharmacists must collaborate with
other health care experts to develop suitable therapy regimens, with the ultimate goal of minimizing mortality from liver
disorders